Inter Pharma Public Stock Beta
| IP Stock | THB 3.50 0.04 1.16% |
Inter Pharma Public fundamentals help investors to digest information that contributes to Inter Pharma's financial success or failures. It also enables traders to predict the movement of Inter Stock. The fundamental analysis module provides a way to measure Inter Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inter Pharma stock.
Inter |
Inter Pharma Public Company Beta Analysis
Inter Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Inter Pharma Beta | 0.5 |
Most of Inter Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inter Pharma Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Inter Pharma Public has a Beta of 0.4979. This is 42.1% lower than that of the Healthcare sector and 64.18% lower than that of the Biotechnology industry. The beta for all Thailand stocks is notably lower than that of the firm.
Inter Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inter Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inter Pharma could also be used in its relative valuation, which is a method of valuing Inter Pharma by comparing valuation metrics of similar companies.Inter Pharma is currently under evaluation in beta category among its peers.
As returns on the market increase, Inter Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Inter Pharma is expected to be smaller as well.
Inter Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0524 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 4.5 B | |||
| Shares Outstanding | 372.52 M | |||
| Shares Owned By Insiders | 47.33 % | |||
| Shares Owned By Institutions | 2.72 % | |||
| Price To Earning | 115.05 X | |||
| Price To Book | 2.69 X | |||
| Price To Sales | 3.66 X | |||
| Revenue | 908.63 M | |||
| Gross Profit | 413.14 M | |||
| EBITDA | 172.3 M | |||
| Net Income | 105.22 M | |||
| Cash And Equivalents | 153.09 M | |||
| Cash Per Share | 0.53 X | |||
| Total Debt | 187.06 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 5.09 X | |||
| Cash Flow From Operations | (41.57 M) | |||
| Earnings Per Share | 0.43 X | |||
| Target Price | 20.0 | |||
| Beta | 0.5 | |||
| Market Capitalization | 5.59 B | |||
| Total Asset | 1.33 B | |||
| Z Score | 17.4 | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.33 B |
About Inter Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inter Pharma Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inter Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inter Pharma Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Inter Stock
Inter Pharma financial ratios help investors to determine whether Inter Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inter with respect to the benefits of owning Inter Pharma security.